New drugs are continually being researched and developed for Non-Hodgkin’s lymphoma. These must be shown to be safe and effective before doctors can prescribe them to patients. Through clinical trials, researchers test the effects of new drugs on a group of volunteers with non-Hodgkin’s lymphoma. Following a strict protocol and using carefully controlled conditions, researchers evaluate the investigational drugs under development and measure the ability of the new drug to treat non-Hodgkin’s lymphoma, its safety, and any possible side effects.
Some patients with non-Hodgkin’s lymphoma are reluctant to take part in clinical trials for fear of getting no treatment at all for their condition. Patients who participate in clinical trials may receive the most effective therapy available for their condition -- or they may receive treatments that are being evaluated for future use. These drugs may be even more effective than the current non-Hodgkin’s lymphoma treatment. The specifics of the clinical trial should be discussed with your doctor.
Incidence and Mortality
Estimated new cases and deaths from acute myeloid leukemia (AML) in the United States in 2014:
New cases: 18,860.
Prognosis and Survival
Advances in the treatment of AML (also called acute myelogenous leukemia, acute nonlymphocytic leukemia [ANLL]) have resulted in substantially improved complete remission (CR) rates. Treatment should be sufficiently aggressive to achieve CR because partial remission offers no substantial survival...
This web site, developed by the nonprofit Coalition of Cancer Cooperative Groups, is an unbiased cancer clinical trial matching and navigation service enabling patients to search for cancer trials based on disease and location.